Calcineurin Inhibition at the Clinical Phase of Prion Disease Reduces Neurodegeneration, Improves Behavioral Alterations and Increases Animal Survival

English version České info

Prion diseases are fatal neurodegenerative disorders characterized by a long pre-symptomatic phase followed by rapid and progressive clinical phase. Although rare in humans, the unconventional infectious nature of the disease raises the potential for an epidemic. Unfortunately, no treatment is currently available. The hallmark event in prion diseases is the accumulation of a misfolded and infectious form of the prion protein (PrP^Sc). Previous reports have shown that PrP^Sc induces endoplasmic reticulum stress and changes in calcium homeostasis in the brain of affected individuals. In this study we show that the calcium-dependent phosphatase Calcineurin (CaN) is hyperactivated both in vitro and in vivo as a result of PrP^Sc formation. CaN activation mediates prion-induced neurodegeneration, suggesting that inhibition of this phosphatase could be a target for therapy. To test this hypothesis, prion infected wild type mice were treated intra-peritoneally with the CaN inhibitor FK506 at the clinical phase of the disease. Treated animals exhibited reduced severity of the clinical abnormalities and increased survival time compared to vehicle treated controls. Treatment also led to a significant increase in the brain levels of the CaN downstream targets pCREB and pBAD, which paralleled the decrease of CaN activity. Importantly, we observed a lower degree of neurodegeneration in animals treated with the drug as revealed by a higher number of neurons and a lower quantity of degenerating nerve cells. These changes were not dependent on PrP^Sc formation, since the protein accumulated in the brain to the same levels as in the untreated mice. Our findings contribute to an understanding of the mechanism of neurodegeneration in prion diseases and more importantly may provide a novel strategy for therapy that is beneficial at the clinical phase of the disease.

Vyšlo v časopise: Calcineurin Inhibition at the Clinical Phase of Prion Disease Reduces Neurodegeneration, Improves Behavioral Alterations and Increases Animal Survival. PLoS Pathog 6(10): e32767. doi:10.1371/journal.ppat.1001138
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001138

Souhrn

Zdroje

1. AguzziA

CalellaAM

2009

Prions: protein aggregation and infectious diseases.

Physiol Rev

1105

1152

2. CollingeJ

2001

Prion diseases of humans and animals: their causes and molecular basis.

Annu Rev Neurosci

519

550

3. BruceME

WillRG

IronsideJW

McConnellI

DrummondD

1997

Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent.

Nature

389

498

501

4. CollingeJ

SidleKC

MeadsJ

IronsideJ

HillAF

1996

Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD.

Nature

383

685

690

5. AguzziA

GlatzelM

2004

vCJD tissue distribution and transmission by transfusion–a worst-case scenario coming true?

Lancet

363

411

412

6. LlewellynCA

HewittP

KnightRS

AmarK

CousensS

2004

Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.

Lancet

363

417

421

7. PedenAH

HeadMW

RitchieDL

BellJE

IronsideJW

2004

Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.

Lancet

364

527

529

8. TrevittCR

CollingeJ

2006

A systematic review of prion therapeutics in experimental models.

Brain

129

2241

2265

9. WeissmannC

AguzziA

2005

Approaches to Therapy of Prion Diseases.

Annu Rev Med

321

344

10. CashmanNR

CaugheyB

2004

Prion diseases - close to effective therapy?

Nat Rev Drug Discov

874

884

11. HetzC

Russelakis-CarneiroM

MaundrellK

CastillaJ

SotoC

2003

Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein.

EMBO J

5435

5445

12. HetzCA

SotoC

2006

Stressing Out the ER: A Role of the Unfolded Protein Response in Prion-Related Disorders.

Curr Mol Med

13. YooBC

KrapfenbauerK

CairnsN

BelayG

BajoM

2002

Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldt-Jakob disease.

Neurosci Lett

334

196

200

14. HetzC

Russelakis-CarneiroM

WalchliS

CarboniS

Vial-KnechtE

2005

The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity.

J Neurosci

2793

2802

15. MansuyIM

2003

Calcineurin in memory and bidirectional plasticity.

Biochem Biophys Res Commun

311

1195

1208

16. GotoS

MatsukadoY

MiharaY

InoueN

MiyamotoE

1986

The distribution of calcineurin in rat brain by light and electron microscopic immunohistochemistry and enzyme-immunoassay.

Brain Res

397

161

172

17. GotoS

MatsukadoY

MiharaY

InoueN

MiyamotoE

1986

Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains.

Acta Neuropathol

150

156

18. WangHG

PathanN

EthellIM

KrajewskiS

YamaguchiY

1999

Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD.

Science

284

339

343

19. GrothRD

DunbarRL

MermelsteinPG

2003

Calcineurin regulation of neuronal plasticity.

Biochem Biophys Res Commun

311

1159

1171

20. ScottLJ

McKeageK

KeamSJ

PloskerGL

2003

Tacrolimus: a further update of its use in the management of organ transplantation.

Drugs

1247

1297

21. LiuJ

FarmerJDJr

LaneWS

FriedmanJ

WeissmanI

1991

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

Cell

807

815

22. RogersTB

InesiG

WadeR

LedererWJ

1995

Use of thapsigargin to study Ca2+ homeostasis in cardiac cells.

Biosci Rep

341

349

23. GuentherK

DeaconRM

PerryVH

RawlinsJN

2001

Early behavioural changes in scrapie-affected mice and the influence of dapsone.

Eur J Neurosci

401

409

24. BetmouniS

ClementsJ

PerryVH

1999

Vacuolation in murine prion disease: an informative artifact.

Curr Biol

R677

R679

25. SiskovaZ

PageA

O'ConnorV

PerryVH

2009

Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping.

Am J Pathol

175

1610

1621

26. PerryVH

CunninghamC

BocheD

2002

Atypical inflammation in the central nervous system in prion disease.

Curr Opin Neurol

349

354

27. AramburuJ

HeitmanJ

CrabtreeGR

2004

Calcineurin: a central controller of signalling in eukaryotes.

EMBO Rep

343

348

28. MullenRJ

BuckCR

SmithAM

1992

NeuN, a neuronal specific nuclear protein in vertebrates.

Development

116

201

211

29. SchmuedLC

HopkinsKJ

2000

Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration.

Toxicol Pathol

30. SotoC

2004

Diagnosing prion diseases: needs, challenges and hopes.

Nat Rev Microbiol

809

819

31. SimVL

CaugheyB

2009

Recent advances in prion chemotherapeutics.

Infect Disord Drug Targets

32. Doh-UraK

IwakiT

CaugheyB

2000

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.

J Virol

4894

4897

33. KorthC

MayBC

CohenFE

PrusinerSB

2001

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.

Proc Natl Acad Sci U S A

9836

9841

34. BarretA

TagliaviniF

ForloniG

BateC

SalmonaM

2003

Evaluation of quinacrine treatment for prion diseases.

J Virol

8462

8469

35. Doh-UraK

IshikawaK

Murakami-KuboI

SasakiK

MohriS

2004

Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models.

J Virol

4999

5006

36. NakajimaM

YamadaT

KusuharaT

FurukawaH

TakahashiM

2004

Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.

Dement Geriatr Cogn Disord

158

163

37. CollingeJ

GorhamM

HudsonF

KennedyA

KeoghG

2009

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.

Lancet Neurol

334

344

38. MangeA

NishidaN

MilhavetO

McMahonHE

CasanovaD

2000

Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.

J Virol

3135

3140

39. AdjouKT

PrivatN

DemartS

DeslysJP

SemanM

2000

MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters.

J Comp Pathol

122

40. McKenzieD

KaczkowskiJ

MarshR

AikenJ

1994

Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection.

J Virol

7534

7536

41. MasulloC

MacchiG

XiYG

PocchiariM

1992

Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy.

J Infect Dis

165

784

785

42. CaugheyB

RaymondGJ

1993

Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells.

J Virol

643

650

43. DiringerH

EhlersB

1991

Chemoprophylaxis of scrapie in mice.

J Gen Virol

457

460

44. LadoganaA

CasacciaP

IngrossoL

CibatiM

SalvatoreM

1992

Sulphate polyanions prolong the incubation period of scrapie-infected hamsters.

J Gen Virol

661

665

45. BoneI

BeltonL

WalkerAS

DarbyshireJ

2008

Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK.

Eur J Neurol

458

464

46. TeradaT

TsuboiY

ObiT

Doh-UraK

MurayamaS

2009

Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.

Acta Neurol Scand

121

127

130

47. TsuboiY

Doh-UraK

YamadaT

2009

Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.

Neuropathology

632

636

48. WhittleIR

KnightRS

WillRG

2006

Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.

Acta Neurochir (Wien)

148

677

679

49. MansuyIM

2003

Calcineurin in memory and bidirectional plasticity.

Biochem Biophys Res Commun

311

1195

1208

50. PritchardDI

2005

Sourcing a chemical succession for cyclosporin from parasites and human pathogens.

Drug Discov Today

688

691

51. SaundersRN

MetcalfeMS

NicholsonML

2001

Rapamycin in transplantation: a review of the evidence.

Kidney Int

52. MatusS

LisbonaF

TorresM

LeonC

ThielenP

2008

The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration.

Curr Mol Med

157

172

53. ReeseLC

ZhangW

DineleyKT

KayedR

TaglialatelaG

2008

Selective induction of calcineurin activity and signaling by oligomeric amyloid beta.

Aging Cell

824

835

54. GhribiO

2006

The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease.

Curr Mol Med

119

133

55. RaoRV

BredesenDE

2004

Misfolded proteins, endoplasmic reticulum stress and neurodegeneration.

Curr Opin Cell Biol

653

662

56. AbdulHM

SamaMA

FurmanJL

MathisDM

BeckettTL

2009

Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.

J Neurosci

12957

12969

57. DineleyKT

HoganD

ZhangWR

TaglialatelaG

2007

Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice.

Neurobiol Learn Mem

217

224

58. TaglialatelaG

HoganD

ZhangWR

DineleyKT

2009

Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition.

Behav Brain Res

200

59. ChenQS

WeiWZ

ShimaharaT

XieCW

2002

Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Neurobiol Learn Mem

354

371

60. BanksWA

RobinsonSM

Diaz-EspinozaR

UrayamaA

SotoC

2009

Transport of prion protein across the blood-brain barrier.

Exp Neurol

218